Nitroimidazoles, Part XXIII--activity of satranidazole series against anaerobic infections.
A large number of nitroimidazoles have been examined for in vitro activity against three anaerobes - Bacteroides fragilis (Bf), a strain of Bf resistant to metronidazole (16a) and Clostridium perfringens and many found to be active. Among these may be mentioned 1-methyl-5-nitroimidazoles carrying N - bound hetetocycles at position 2, such as satranidazole 1a, 1b, 1c, 1k, 1n and 1v which are at least twice as active as metronidazole (16a), ornidazole (16b) and tinidazole (16c). Even more active are 5-nitroimidazolyl benzimidazole 5d, -thiazolidinone 6b and thiadiazolidine dioxide 8a. Many other types of compounds derived from 1-methyl-2-amino-5-nitroimidazole are feebly active. Among 5-nitroimidazoles with a carbon substituent at position 2, 16a, 16b and 16c are equiactive while dimetridazole 14f is more active than 16a against Bf. Some 2-vinyl derivatives are very potent, with 18f and 18i being outstanding. Activity better than that of metronidazole is seen for nitroimidazooxazepines, e.g. 29d. 5-Nitroimidazoles are more active against anaerobes than 4-nitro isomers. Antianaerobic and antiamoebic activities generally run parallel in these classes of compounds. The study has led to the elaboration of the antianaerobic profile of satranidazole 1a.
Nagarajan
K
K
Hindustan CIBA-GEIGY Research Centre, Bombay, India.
Gowrishankar
R
R
Arya
V P
VP
George
T
T
Nair
M D
MD
Shenoy
S J
SJ
Sudarsanam
V
V
D000563:Amebicides / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy; D001441:Bacteroides fragilis / Q000187:drug effects; D003016:Clostridium perfringens / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009593:Nitroimidazoles / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000563:Amebicides; D009593:Nitroimidazoles; C034473:satranidazole